Yarrow is advancing YB-101—a potential first-in-class anti-TSHR antibody, designed to directly disrupt the central mechanism driving both Graves’ disease (“GD”) and thyroid eye disease (“TED”) Dosing commenced in Phase 2a/2b GD trial following FDA Fast Track Designation, with Phase 2a data expected
